ABSTRACT

The present invention provides a sonfenib or donafenib (TKI) oral preparation, comprising a TKI molecular-level mixture and self-assembled polymer materials. The present application also provides an application of the TKI oral preparation. The two self-assembled polymer materials in the TKI oral preparation provided by the present application perform coordinated regulation with TKI guest molecules to reduce premature degradation or efflux of a drug caused by CYP3A4/A5, CYP2D6, CYP2C8 or P-gp of P450 enzymes in epithelial cells of the gastrointestinal tract mucosa during an absorption process of the oral preparation, and reduce decreased absorption caused by rapid packing after the drug is quickly dissolved out of a molecular-level composition. Therefore, the oral preparation can achieve the same curative effect at a lower dose, features lower C_{max} and AUC_{0-t} variations, reduces of the risk of being non-effective or toxic, and would not be affected by food; in addition, the oral preparation significantly reduces dose-related side effects, improves patient compliance, and has good physical and chemical stability.

[**FIG. 7**]